Pulmonary function assessment post-left ventricular assist device implantation

Pavol Sajgalik; Chul Ho Kim; John M. Stulak; Sudhir S. Kushwaha; Simon Maltais; David L. Joyce; Lyle D. Joyce; Bruce D. Johnson; John A. Schirger

doi:10.1002/ehf2.12348

Pulmonary function assessment post-left ventricular assist device implantation

Pavol Sajgalik, Chul Ho Kim, John M. Stulak, Sudhir S. Kushwaha, Simon Maltais, David L. Joyce, Lyle D. Joyce, Bruce D. Johnson, John A. Schirger

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV₁)] and diffusing capacity of the lung for carbon monoxide (D_LCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant D_LCO decrease (−23%) since pre-implantation (P < 0.001). ΔD_LCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔD_LCO to ΔPCWP (r = 0.50, P < 0.01) and ΔD_LCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV₁, FVC, and FEV₁/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV₁ changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV₁/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔD_LCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of D_LCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔD_LCO within 6 months post-operative was associated with survival.

Original language	English (US)
Pages (from-to)	53-61
Number of pages	9
Journal	ESC Heart Failure
Volume	6
Issue number	1
DOIs	https://doi.org/10.1002/ehf2.12348
State	Published - Feb 2019

Keywords

Continuous flow pumps
D
Pulmonary circulation

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1002/ehf2.12348

Cite this

@article{bbae8467b4724a899ecb6e6548868e07,

title = "Pulmonary function assessment post-left ventricular assist device implantation",

abstract = "Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.",

keywords = "Continuous flow pumps, D, Pulmonary circulation",

author = "Pavol Sajgalik and Kim, {Chul Ho} and Stulak, {John M.} and Kushwaha, {Sudhir S.} and Simon Maltais and Joyce, {David L.} and Joyce, {Lyle D.} and Johnson, {Bruce D.} and Schirger, {John A.}",

note = "Funding Information: This study was supported by the Mayo Clinic Cardiovascular Prospective Project Award and the National Institutes of Health grant HL71478 (B.D.J.). Mayo Clinic does not endorse specific products or services included in this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: {\textcopyright} 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.",

year = "2019",

month = feb,

doi = "10.1002/ehf2.12348",

language = "English (US)",

volume = "6",

pages = "53--61",

journal = "ESC heart failure",

issn = "2055-5822",

publisher = "The Heart Failure Association of the European Society of Cardiology",

number = "1",

}

TY - JOUR

T1 - Pulmonary function assessment post-left ventricular assist device implantation

AU - Sajgalik, Pavol

AU - Kim, Chul Ho

AU - Stulak, John M.

AU - Kushwaha, Sudhir S.

AU - Maltais, Simon

AU - Joyce, David L.

AU - Joyce, Lyle D.

AU - Johnson, Bruce D.

AU - Schirger, John A.

N1 - Funding Information: This study was supported by the Mayo Clinic Cardiovascular Prospective Project Award and the National Institutes of Health grant HL71478 (B.D.J.). Mayo Clinic does not endorse specific products or services included in this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Publisher Copyright: © 2018 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology.

PY - 2019/2

Y1 - 2019/2

N2 - Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.

AB - Aim: The lungs—and particularly the alveolar-capillary membrane—may be sensitive to continuous flow (CF) and pulmonary pressure alterations in heart failure (HF). We aimed to investigate long-term effects of CF pumps on respiratory function. Methods and results: We conducted a retrospective study of patients with end-stage HF at our institution. We analysed pulmonary function tests [e.g. forced vital capacity (FVC) and forced expiratory volume in 1 s (FEV1)] and diffusing capacity of the lung for carbon monoxide (DLCO) from before and after left ventricular assist device (LVAD) implantation and compared them with invasive haemodynamic studies. Of the 274 patients screened, final study analysis involved 44 patients with end-stage HF who had CF LVAD implantation between 1 February 2007 and 31 December 2015 at our institution. These patients [mean (standard deviation, SD) age, 50 (9) years; male sex, n = 33, 75%] received either the HeartMate II (Thoratec Corp.) pump (77%) or the HeartWare (HeartWare International Inc.) pump. The mean (SD) left ventricular ejection fraction was 21% (13%). At a median of 237 days post-LVAD implantation, we observed significant DLCO decrease (−23%) since pre-implantation (P < 0.001). ΔDLCO had an inverse relationship with changes in pulmonary capillary wedge pressure (PCWP) and right atrial pressure (RAP) from pre-LVAD to post-LVAD implantation: ΔDLCO to ΔPCWP (r = 0.50, P < 0.01) and ΔDLCO to ΔRAP (r = 0.39, P < 0.05). We observed other reductions in FEV1, FVC, and FEV1/FVC between pre-LVAD and post-LVAD implantation. In mean (SD) values, FEV1 changed from 2.3 (0.7) to 2.1 (0.7) (P = 0.005); FVC decreased from 3.2 (0.8) to 2.9 (0.9) (P = 0.01); and FEV1/FVC went from 0.72 (0.1) to 0.72 (0.1) (P = 0.50). Landmark survival analysis revealed that ΔDLCO from 6 months after LVAD implantation was predictive of death for HF patients [hazard ratio (95% confidence interval), 0.60 (0.28–0.98); P = 0.03]. Conclusions: Pulmonary function did not improve after LVAD implantation. The degree of DLCO deterioration is related to haemodynamic status post-LVAD implantation. The ΔDLCO within 6 months post-operative was associated with survival.

KW - Continuous flow pumps

KW - D

KW - Pulmonary circulation

UR - http://www.scopus.com/inward/record.url?scp=85054867357&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054867357&partnerID=8YFLogxK

U2 - 10.1002/ehf2.12348

DO - 10.1002/ehf2.12348

M3 - Article

C2 - 30311748

AN - SCOPUS:85054867357

VL - 6

SP - 53

EP - 61

JO - ESC heart failure

JF - ESC heart failure

SN - 2055-5822

IS - 1

ER -

Pulmonary function assessment post-left ventricular assist device implantation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this